Sarvananda Shobiga, Earnshaw Stan, Hughes Ian, Sivakumaran Pathmanathan, Sriram Krishna Bajee
Department of Respiratory Medicine, Gold Coast University Hospital, 1 Hospital Boulevard, Gold Coast, Queensland, 4215, Australia.
Gold Coast Hospital and Health Service, Gold Coast, Queensland, 4215, Australia.
Intern Med J. 2025 Aug;55(8):1281-1292. doi: 10.1111/imj.70137. Epub 2025 Jul 2.
Patients with obstructive sleep apnoea (OSA) and/or obesity hypoventilation syndrome (OHS) are at increased risk of developing pulmonary hypertension (PH). The presence of PH is associated with a worse prognosis. The primary treatment for most patients with OSA/OHS is positive airway pressure (PAP). The aim of this study was to systematically review the effects of PAP therapy on pulmonary artery (PA) pressure in patients with OSA/OHS and PH.
Does PAP therapy improve pulmonary artery pressure in patients with OSA/OHS and PH?
Two independent investigators searched studies in MEDLINE, Embase and Cochrane Library. A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Inclusion criteria included studies involving adult OSA/OHS patients treated with CPAP/BPAP, with PA pressure ≥20 mmHg before treatment. Data synthesis utilised random-effects meta-analysis to estimate treatment effect.
The search identified 1373 studies, with eight meeting inclusion criteria. Baseline characteristics of patients with PH were a mean age of 53 years, 86% male, a mean apnoea-hypopnea index (AHI) of 64 events/h and a mean BMI of 33 kg/m. Meta-analysis revealed a reduction in PA pressure after PAP therapy (mean difference -8.62 mmHg, 95% CI: 4.01-13.22, P < 0.001). However, there was considerable between-study heterogeneity (I = 97.5%).
This study indicates that PAP therapy reduces PA pressure in patients with OSA/OHS, indicating potential benefits in managing PH. Further research is warranted to elucidate optimal PAP therapy protocols and long-term outcomes.
阻塞性睡眠呼吸暂停(OSA)和/或肥胖低通气综合征(OHS)患者发生肺动脉高压(PH)的风险增加。PH的存在与预后较差相关。大多数OSA/OHS患者的主要治疗方法是气道正压通气(PAP)。本研究的目的是系统评价PAP治疗对OSA/OHS合并PH患者肺动脉(PA)压力的影响。
PAP治疗能否改善OSA/OHS合并PH患者的肺动脉压力?
两名独立研究者检索了MEDLINE、Embase和Cochrane图书馆中的研究。按照系统评价和Meta分析的首选报告项目指南进行系统评价和Meta分析。纳入标准包括涉及接受持续气道正压通气(CPAP)/双水平气道正压通气(BPAP)治疗的成年OSA/OHS患者,治疗前PA压力≥20 mmHg的研究。数据合成采用随机效应Meta分析来估计治疗效果。
检索到1373项研究,其中8项符合纳入标准。PH患者的基线特征为平均年龄53岁,男性占86%,平均呼吸暂停低通气指数(AHI)为64次/小时,平均体重指数(BMI)为33 kg/m²。Meta分析显示PAP治疗后PA压力降低(平均差值-8.62 mmHg,95%置信区间:4.01-13.22,P<0.001)。然而,研究间存在相当大的异质性(I²=97.5%)。
本研究表明PAP治疗可降低OSA/OHS患者的PA压力,提示在管理PH方面可能有益。有必要进一步研究以阐明最佳PAP治疗方案和长期结局。